Geoffrey Porges
Stock Analyst at SVB Leerink
(1.34)
# 3,647
Out of 5,116 analysts
121
Total ratings
43.37%
Success rate
-6.31%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Geoffrey Porges
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PFE Pfizer | Maintains: Market Perform | $52 → $56 | $25.03 | +123.73% | 10 | Dec 15, 2021 | |
| RCUS Arcus Biosciences | Maintains: Outperform | $68 → $100 | $23.12 | +332.53% | 8 | Nov 18, 2021 | |
| REGN Regeneron Pharmaceuticals | Maintains: Outperform | $798 → $850 | $783.71 | +8.46% | 16 | Nov 5, 2021 | |
| HALO Halozyme Therapeutics | Maintains: Outperform | $50 → $48 | $68.41 | -29.83% | 2 | Nov 3, 2021 | |
| AMGN Amgen | Maintains: Market Perform | $234 → $216 | $333.96 | -35.32% | 12 | Nov 3, 2021 | |
| ABBV AbbVie | Maintains: Outperform | $142 → $135 | $229.89 | -41.28% | 16 | Nov 1, 2021 | |
| ROIV Roivant Sciences | Initiates: Outperform | $11 | $22.50 | -51.11% | 1 | Nov 1, 2021 | |
| GILD Gilead Sciences | Maintains: Outperform | $77 → $75 | $125.67 | -40.32% | 14 | Oct 29, 2021 | |
| SNY Sanofi | Upgrades: Outperform | n/a | $48.36 | - | 2 | Sep 27, 2021 | |
| TBPH Theravance Biopharma | Maintains: Outperform | $29 → $10 | $18.73 | -46.61% | 9 | Sep 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $875 → $750 | $8.50 | +8,723.43% | 8 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $170 → $175 | $462.99 | -62.20% | 9 | Jul 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $96 → $84 | $34.00 | +147.06% | 3 | May 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $48.96 | - | 1 | Mar 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $61 | $18.25 | +234.25% | 2 | Nov 28, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $176.33 | - | 8 | Mar 16, 2017 |
Pfizer
Dec 15, 2021
Maintains: Market Perform
Price Target: $52 → $56
Current: $25.03
Upside: +123.73%
Arcus Biosciences
Nov 18, 2021
Maintains: Outperform
Price Target: $68 → $100
Current: $23.12
Upside: +332.53%
Regeneron Pharmaceuticals
Nov 5, 2021
Maintains: Outperform
Price Target: $798 → $850
Current: $783.71
Upside: +8.46%
Halozyme Therapeutics
Nov 3, 2021
Maintains: Outperform
Price Target: $50 → $48
Current: $68.41
Upside: -29.83%
Amgen
Nov 3, 2021
Maintains: Market Perform
Price Target: $234 → $216
Current: $333.96
Upside: -35.32%
AbbVie
Nov 1, 2021
Maintains: Outperform
Price Target: $142 → $135
Current: $229.89
Upside: -41.28%
Roivant Sciences
Nov 1, 2021
Initiates: Outperform
Price Target: $11
Current: $22.50
Upside: -51.11%
Gilead Sciences
Oct 29, 2021
Maintains: Outperform
Price Target: $77 → $75
Current: $125.67
Upside: -40.32%
Sanofi
Sep 27, 2021
Upgrades: Outperform
Price Target: n/a
Current: $48.36
Upside: -
Theravance Biopharma
Sep 16, 2021
Maintains: Outperform
Price Target: $29 → $10
Current: $18.73
Upside: -46.61%
Aug 10, 2021
Maintains: Outperform
Price Target: $875 → $750
Current: $8.50
Upside: +8,723.43%
Jul 30, 2021
Maintains: Underperform
Price Target: $170 → $175
Current: $462.99
Upside: -62.20%
May 10, 2021
Maintains: Market Perform
Price Target: $96 → $84
Current: $34.00
Upside: +147.06%
Mar 23, 2021
Downgrades: Market Perform
Price Target: n/a
Current: $48.96
Upside: -
Nov 28, 2018
Initiates: Outperform
Price Target: $61
Current: $18.25
Upside: +234.25%
Mar 16, 2017
Downgrades: Market Perform
Price Target: n/a
Current: $176.33
Upside: -